Showing 4841-4850 of 7543 results for "".
- MELA Sciences and Columbia University Imaging Experts Columbia Team Explore Potential Next Generation MelaFind Enhancementshttps://practicaldermatology.com/news/20140902-mela_sciences_and_columbia_university_imaging_experts_columbia_team_explore_potential_next_generation_melafind_enhancements/2459135/MELA Sciences, Inc.has executed a research agreement with Columbia University in which MELA and Columbia will collaborate to explore potential next generation capabilities and features of the MelaFind system and other enhancements to the system's range and ease of use. The company will have exclu
- Promius Pharma, LLC: Finalist for PM360 Company of the Year Awardhttps://practicaldermatology.com/news/20140828-promius_pharma_llc_finalist_for_pm360_company_of_the_year_award/2459136/Promius Pharma, LLC has been named as a Trailblazer Company of the Year finalist by PM360, a publication that covers the pharmaceutical, biotech and medical device industries. Promius is one of three finalists in the category of Company of the Y
- Carma Laboratories Introduces New Carmex® Cold Sore Treatmenthttps://practicaldermatology.com/news/20140820-carma_laboratories_introduces_new_carmex_cold_sore_treatment/2459142/Carma Laboratories, Inc., the maker of Carmex® lip balm products, has launched the new Carmex® Cold Sore Treatment. This product features TriPLEX™ Formula advanced technology, which combines three different optical brightener and filler technologies that each provide unique appea
- Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, And Sinopharm A-Think Pharmaceutical Co., LTDhttps://practicaldermatology.com/news/20140818-provectus_signs_memorandum_of_understanding_with_sinopharm-china_state_institute_of_pharmaceutical_industry_and_sinopharm_a-think_pharmaceutical_co_lt/2459143/Negotiations on Licensing PV-10 in China Opened Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with
- Syneron Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosishttps://practicaldermatology.com/news/20140815-syneron_introduces_new_fda-cleared_5mm_spot_size_for_treatment_of_onychomycosis/2459145/Syneron Medical Ltd. launched a new handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series. The introduction of this new FDA-cleared handp
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- 'Sun Safe' Study: Children Seek Shade if Availablehttps://practicaldermatology.com/news/20140812-sun_safe_study_children_seek_shade_if_available/2459147/A new study by the founder of Sun Safe Soccer reveals nearly two-thirds of children will use shade tents during soccer breaks without any prompting from coaches. The study, published in JAMA Dermatology, was conducted by Ian Maher, M.D., who developed the Sun Safe Soccer skin cancer preve
- Justin Chickles Joins myoscience as Vice President of Commercial Development & Johanna Beckmen Becomes General Manager of Aestheticshttps://practicaldermatology.com/news/20140812-justin_chickles_joins_myoscience_as_vice_president_of_commercial_development__johanna_beckmen_becomes_general_manager_of_aesthetics/2459148/Justin Chickles is now Vice President of Commercial Development and Johanna Beckmen is now promoted to General Manager of Aesthetics of Myoscience, Inc. Chickles Said, "Myoscience's ioveradegrees treatment is poised to become a transformative therapy for patients living with pain.The pas
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101.
- National Call-to-Action on Skin Cancer Preventionhttps://practicaldermatology.com/news/20140806-national_call-to-action_on_skin_cancer_prevention/2459152/The American Academy of Dermatology Association (AADA) recently joined with the U.S. Department of Health and Human Services' (HHS) Office of the Surgeon General and Centers for Disease Control and Prevention (CDC) to issue a national call-to-action on skin cancer prevention. T